Cardiometabolic Diseases Market Report 2026

The cardiometabolic diseases market size has grown steadily in recent years. It will grow from $115.27 billion in 2025 to $120.13 billion in 2026 at a compound annual growth rate (CAGR) of 4.2%. The growth in the historic period can be attributed to rising prevalence of obesity and diabetes, increased incidence of hypertension and heart failure, expansion of urban sedentary lifestyles, growing awareness of cardiometabolic risks, availability of established therapeutic classes.

The cardiometabolic diseases market size is expected to see steady growth in the next few years. It will grow to $143.73 billion in 2030 at a compound annual growth rate (CAGR) of 4.6%. The growth in the forecast period can be attributed to increasing demand for personalized medicine, rising adoption of digital health tools, expansion of early screening programs, growing focus on lifestyle-based interventions, increasing development of novel cardiometabolic drugs. Major trends in the forecast period include increasing focus on integrated disease management approaches, rising adoption of combination drug therapies, growing use of personalized treatment strategies, expansion of preventive cardiometabolic care models, enhanced emphasis on long-term disease monitoring.

The increasing prevalence of obesity is expected to drive the growth of the cardiometabolic disease market in the coming years. Obesity is a multifaceted condition marked by excessive body fat accumulation, resulting in higher body weight and associated health issues. The rise in obesity is largely due to sedentary lifestyles and high-calorie diets, which contribute to cardiovascular risk factors such as type 2 diabetes, hypertension, dyslipidemia, and sleep disorders. Management of cardiometabolic diseases focuses on mitigating these risks by improving metabolic health and reducing complications linked to obesity. For example, in May 2025, according to the Office for Health Improvement and Disparities (OHID), a UK government agency, approximately 64.5% of adults (18+) in England were estimated to be overweight or living with obesity in 2023-2024, slightly higher than 64% in the previous period (2022-2023). Consequently, the high prevalence of obesity is fueling the growth of the cardiometabolic diseases market.

Major companies are active in the cardiometabolic diseases market, focusing on the adoption of advanced technologies such as the launch of cardiac disease detection platforms to improve early diagnosis and monitoring of cardiovascular conditions. The launch of a cardiac disease detection platform involves introducing a specialized system designed to detect, monitor, and evaluate cardiovascular conditions using advanced diagnostic technologies, sensors, and data analytics, with the goal of enabling early detection, enhancing patient outcomes, and supporting clinical decision-making. For example, in February 2023, Eko Health Inc., a US-based developer of digital health technologies for heart and lung diseases, launched the Sensora cardiac disease detection platform. It incorporates artificial intelligence (AI) that accurately identifies structural murmurs, a sign of valvular heart disease (VHD), along with care pathway analytics software that provides metrics and insights into the patient journey within the healthcare system. This digital stethoscope is used to capture and analyze electrical impulses and heartbeats.

In August 2023, Novo Nordisk, a Denmark-based healthcare company, acquired Embark Biotech for $498 million. This acquisition aims to strengthen Novo Nordisk’s pipeline for treating obesity and other cardiometabolic diseases. Embark Biotech, also based in Denmark, develops therapies for cardiometabolic conditions, including obesity and type 2 diabetes.

Major companies operating in the cardiometabolic diseases market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi SA, Kowa Company Ltd., Abbott Laboratories, Takeda Pharmaceutical Company, Eli Lilly and Company, Novo Nordisk A/S, Siemens Healthineers, Boehringer Ingelheim International GmbH, Becton Dickinson and Company, Stryker Corporation, AstraZeneca Plc, Viatris Inc., Boston Scientific, Astellas Pharma Inc., Terumo Corporation, Edwards Lifesciences, Alnylam Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Cardax Inc.

North America was the largest region in the cardiometabolic diseases market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cardiometabolic diseases market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cardiometabolic diseases market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the cardiometabolic diseases market by increasing costs of imported active pharmaceutical ingredients, medical devices, diagnostic tools, and drug delivery systems used in disease management. Healthcare providers and pharmaceutical manufacturers in North America and Europe are most affected due to globalized supply chains, while emerging markets face higher treatment costs. These tariffs are contributing to price pressures and reimbursement challenges. However, they are also driving domestic drug manufacturing, regional API production, and investments in local healthcare supply chains to improve long-term treatment accessibility.

The cardiometabolic diseases market research report is one of a series of new reports that provides cardiometabolic diseases market statistics, including cardiometabolic diseases industry global market size, regional shares, competitors with a cardiometabolic diseases market share, detailed cardiometabolic diseases market segments, market trends and opportunities, and any further data you may need to thrive in the cardiometabolic diseases industry. This cardiometabolic diseases market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Cardiometabolic diseases are a group of related health conditions that affect both the cardiovascular and metabolic systems. These conditions frequently occur together and share common risk factors, including obesity, lack of physical activity, an unhealthy diet, and genetic susceptibility.

The primary types of cardiometabolic diseases include chronic or congestive heart failure, hypertension, type 2 diabetes, and obesity. Congestive heart failure is a long-term condition in which the heart's ability to pump blood effectively is impaired. Treatments include ACE inhibitors, diuretics, glucophage, liposuction, and other therapies. These treatments are available in various dosages such as tablets, injections, and different routes of administration including oral and intravenous, and are utilized by various end-users such as clinics, hospitals, and others.

The cardiometabolic diseases market consists of revenues earned by entities by providing services such as non-invasive CAD testing, cardio-preventive care, behavioral counseling, and clinical assessment. The market value includes the value of related goods sold by the service provider or included within the service offering. The cardiometabolic diseases market also includes sales of medications, blood glucose monitoring devices, blood pressure monitors, cholesterol testing kits, and weight management products used to provide cardiometabolic diseases services. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.